Navelbine (Vinorelbine)

Vinorelbine, the active ingredient in Navelbine, is a Vinca alkaloid presented as an oral formulation for oral use. It is used in the treatment of certain advanced cancers, specifically non‑small cell lung cancer and metastatic breast cancer, in adult patients.

GNH USA supplies Navelbine as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Vinorelbine is a chemotherapy agent that interferes with microtubule dynamics in malignant cells, making it useful for several solid‑tumor indications. - Non‑small cell lung cancer: improves disease control and survival in adults with advanced NSCLC. - Metastatic breast cancer: provides tumor response and disease stabilization in adult patients with metastatic disease. - Combination therapy: is often administered together with other cytotoxic agents to enhance overall response rates in the above cancers.

Vinorelbine can cause a range of adverse reactions, from mild to severe. Patients should be monitored regularly for any new symptoms.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Neutropenia: reduced white blood cell count increasing infection risk. - Fatigue: persistent tiredness affecting daily activities. - Constipation: decreased bowel movements.

Serious or Rare Side Effects: - Severe neutropenia with fever: may indicate life‑threatening infection. - Pulmonary toxicity: cough, dyspnea, or interstitial pneumonitis. - Peripheral neuropathy: tingling or numbness in extremities.

Before initiating therapy, clinicians should assess baseline health status and monitor for specific risks. - Blood count monitoring: perform complete blood counts before each cycle. - Liver function assessment: evaluate hepatic enzymes regularly. - Pulmonary evaluation: watch for new respiratory symptoms. - Pregnancy avoidance: drug is contraindicated in pregnancy (Category D). - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Vinorelbine may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase vinorelbine exposure. - Concurrent myelosuppressive agents: can exacerbate bone‑marrow toxicity. - Live vaccines: risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce drug levels. - Anticoagulants (e.g., warfarin): monitor coagulation parameters. - Diuretics: watch for electrolyte disturbances.